Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Yvonne de Jong:

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. Peterse EFP et al. Br J Cancer. (2018)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. de Jong Y et al. Oncogenesis. (2018)

Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Speetjens FM et al. Curr Opin Oncol. (2016)

Search results

Items: 1 to 20 of 21

1.

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival.

de Jong Y, Bennani F, van Oosterwijk JG, Alberti G, Baranski Z, Wijers-Koster P, Venneker S, Briaire-de Bruij IH, van de Akker BE, Baelde H, Cleton-Jansen AM, van de Water B, Danen EHJ, Bovée JVMG.

J Bone Oncol. 2019 Nov 17;19:100268. doi: 10.1016/j.jbo.2019.100268. eCollection 2019 Dec.

2.

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG.

Cancers (Basel). 2019 Dec 2;11(12). pii: E1918. doi: 10.3390/cancers11121918.

3.

Low Geographic and Subspecific Variation in the Loud Call of the Widespread and Phenotypically Cryptic Northern Lesser Galago (Galago senegalensis) Suggests Taxonomic Uniformity.

Svensson MS, Butynski TM, de Jong YA, Bearder SK, Schneiderová I, Nijman V.

Folia Primatol (Basel). 2019;90(5):300-318. doi: 10.1159/000499654. Epub 2019 Aug 15.

PMID:
31416079
4.

Vocal Repertoire and Intraspecific Variation within Two Loud Calls of the Small-Eared Greater Galago (Otolemur garnettii) in Tanzania and Kenya.

Bettridge CM, Kenworthy SP, Butynski TM, de Jong YA, de Kort SR.

Folia Primatol (Basel). 2019;90(5):319-335. doi: 10.1159/000500260. Epub 2019 Aug 15.

PMID:
31416067
5.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

6.

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG.

J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.

7.

An annotated checklist of mammals of Kenya.

Musila S, Monadjem A, Webala PW, Patterson BD, Hutterer R, De Jong YA, Butynski TM, Mwangi G, Chen ZZ, Jiang XL.

Zool Res. 2019 Jan 18;40(1):3-52. doi: 10.24272/j.issn.2095-8137.2018.059. Epub 2018 Oct 17.

8.

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A, Bovée JVMG.

Oncogenesis. 2018 Sep 21;7(9):74. doi: 10.1038/s41389-018-0084-0.

9.

Sleep patterns, daytime predation, and the evolution of diurnal sleep site selection in lorisiforms.

Svensson MS, Nekaris KAI, Bearder SK, Bettridge CM, Butynski TM, Cheyne SM, Das N, de Jong YA, Luhrs AM, Luncz LV, Maddock ST, Perkin A, Pimley E, Poindexter SA, Reinhardt KD, Spaan D, Stark DJ, Starr CR, Nijman V.

Am J Phys Anthropol. 2018 Jul;166(3):563-577. doi: 10.1002/ajpa.23450.

PMID:
29989160
10.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

11.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

12.

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG.

Transl Oncol. 2017 Aug;10(4):546-554. doi: 10.1016/j.tranon.2017.05.007. Epub 2017 Jun 24.

13.

Screening for psychosis risk among adolescents in Child and Adolescent Mental Health Services: a description of the first step with the 16-item version of the Prodromal Questionnaire (PQ-16).

de Jong Y, Mulder CL, Boon AE, Deen M, van 't Hof M, van der Gaag M.

Early Interv Psychiatry. 2018 Aug;12(4):669-676. doi: 10.1111/eip.12362. Epub 2016 Nov 9.

PMID:
27860294
14.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

15.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

16.

Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.

Speetjens FM, de Jong Y, Gelderblom H, Bovée JV.

Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300. Review.

PMID:
27166664
17.

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.

Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

Genes Cancer. 2015 Nov;6(11-12):503-12.

18.

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.

Baranski Z, de Jong Y, Ilkova T, Peterse EF, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JV, Danen EH.

Oncotarget. 2015 Nov 3;6(34):36113-25. doi: 10.18632/oncotarget.5333.

19.
20.

Construction costs, chemical composition and payback time of high- and low-irradiance leaves.

Poorter H, Pepin S, Rijkers T, de Jong Y, Evans JR, Körner C.

J Exp Bot. 2006;57(2):355-71. Epub 2005 Nov 22.

PMID:
16303828

Supplemental Content

Loading ...
Support Center